Pricing Log in Create free account
Sunday 11 October 2026 Export all BMY data to Excel Powerpack

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.12 0.46 −0.77%
Market cap
$121.7B
P/E
13.0×
Fwd P/E
11.2×
Dividend yield
4.26%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company 10-K filed Feb 11, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 11:35 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 12, 2025: 10 added · 8 removed · 52 modified; 10 with only figures updated; 1 moved without change

  1. Modified · General

    Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger.

69 more changes in this Item, word by word, in Powerpack.

Powerpack